We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+17.73%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$717M
AUM Growth
+$143M
Cap. Flow
+$179M
Cap. Flow %
24.96%
Top 10 Hldgs %
42.64%
Holding
176
New
63
Increased
14
Reduced
29
Closed
31

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$15.9M
2
RCUS icon
Arcus Biosciences
RCUS
+$9.44M
3
AVTX icon
Avalo Therapeutics
AVTX
+$9.44M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$9.12M
5
BPMC
Blueprint Medicines
BPMC
+$8.44M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$20.7M
2
SLNO
Soleno Therapeutics
SLNO
+$10.7M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$8.35M
4
NUVL
Nuvalent
NUVL
+$8.24M
5
AMGN icon
Amgen
AMGN
+$8.18M

Sector Composition

Rank Sector Weight
1 Healthcare 44.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMLX icon
101
Amylyx Pharmaceuticals
AMLX
$2.26B
$890K 0.12%
274,551
– –
PRQR icon
102
ProQR Therapeutics
PRQR
$243M
$880K 0.12%
483,583
– –
RNAC icon
103
Cartesian Therapeutics
RNAC
$229M
$841K 0.12%
52,193
-190,177
-78% -$2.97M
KZR
104
DELISTED
Kezar Life Sciences
KZR
$827K 0.12%
106,899
+20,000
+23% +$121K
VERV
105
DELISTED
Verve Therapeutics
VERV
$823K 0.11%
+170,000
New +$987K
IMUX icon
106
Immunic
IMUX
$190M
$814K 0.11%
49,350
– –
ITOS
107
DELISTED
iTeos Therapeutics
ITOS
$802K 0.11%
78,574
– –
JBIO
108
Jade Biosciences
JBIO
$1.2B
$769K 0.11%
10,513
– –
VERU icon
109
Veru
VERU
$36M
$728K 0.1%
94,638
– –
LYEL icon
110
Lyell Immunopharma
LYEL
$317M
$726K 0.1%
26,303
– –
MIST icon
111
Milestone Pharmaceuticals
MIST
$138M
$708K 0.1%
466,019
– –
ABOS icon
112
Acumen Pharmaceuticals
ABOS
$155M
$661K 0.09%
266,435
– –
INBX icon
113
Inhibrx
INBX
$1.2B
$660K 0.09%
42,123
-187,877
-82% -$2.64M
ALLK
114
DELISTED
Allakos
ALLK
$635K 0.09%
972,675
– –
IMTX icon
115
Immatics
IMTX
$1.18B
$564K 0.08%
49,415
– –
BMEA icon
116
PUT
Biomea Fusion
BMEA
$84.6M
$535K 0.07%
+53,000
New +$344K
NYXH
117
Nyxoah
NYXH
$140M
$484K 0.07%
50,699
– –
NAMS icon
118
CALL
NewAmsterdam Pharma
NAMS
$3.25B
$483K 0.07%
+29,100
New +$503K
VTYX
119
DELISTED
Ventyx Biosciences
VTYX
$420K 0.06%
192,647
-250,000
-56% -$575K
ELEV
120
DELISTED
Elevation Oncology
ELEV
$414K 0.06%
690,089
– –
FTH
121
Faeth Therapeutics
FTH
$702M
$389K 0.05%
32,500
– –
LRMR icon
122
Larimar Therapeutics
LRMR
$397M
$383K 0.05%
58,528
-265,000
-82% -$2.13M
DFTX
123
Definium Therapeutics
DFTX
$5.78B
$356K 0.05%
62,481
-100,000
-62% -$696K
KPTI icon
124
Karyopharm Therapeutics
KPTI
$43.5M
$340K 0.05%
27,290
– –
CMMB
125
Chemomab Therapeutics
CMMB
$11.4M
$335K 0.05%
53,348
– –
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Ikarian Capital held 176 positions worth $717M, up 25% from $574M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Ikarian Capital deployed $179M of net new capital in Q3 2024, opening 63 new positions and adding to 14 existing holdings. Its largest new stake was BeOne Medicines Ltd: 88,167 shares worth $1.64M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 56% a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $20.7M trimmed.

  • Ikarian Capital's largest Q3 2024 buy was BeOne Medicines Ltd: 88,167 shares worth $1.64M.
  • Ikarian Capital added most to Arcus Biosciences in Q3 2024, an estimated $9.44M increase.
  • Ikarian Capital's biggest Q3 2024 reduction was Sarepta Therapeutics, cutting an estimated $20.7M.
  • Ikarian Capital fully exited Immunovant in Q3 2024, selling an estimated $8.17M.
  • Ikarian Capital's ten largest holdings make up 43% of its $717M portfolio in Q3 2024.
  • Ikarian Capital opened 63 new positions and closed 31 in Q3 2024.
  • Ikarian Capital's portfolio value rose 25% quarter-over-quarter to $717M.

Based on Ikarian Capital's 13F filing for Q3 2024, filed 14 Nov 2024.